Urogen Pharma Ltd (URGN) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket
 


Urogen Pharma Ltd   (NASDAQ: URGN)


Urogen Pharma Ltd's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Urogen Pharma Ltd's ROI in the third quarter of 2026?
Urogen Pharma Ltd recorded a cumulative net loss of $-66 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -35.37%.

Within the Healthcare sector 511 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 2250 to 3961.

Definition and Formula of Return on Investment



Return On Investment (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM -0.38 % -21.11 % -31.3 % -28.47 % -10.65 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 198 191 201 154 143
Return On Investment (TTM) -35.37 % -56.73 % -80.87 % -92.52 % -88.24 %
URGN's Overall Ranking # 3961 # 2250 # 2924 # 3619 #
Seq. Investment Change TTM 7.99 % 4.48 % -0.7 % -11.08 % -14.48 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -66 -98 -133 -153 -165




Return On Investment URGN's Ranking
Within: No.
Industry # 223
Sector # 512
Overall # 3961

Return On Investment Statistics
High Average Low
-28.56 %
-80.68 %
-113.85 %
(Dec 31 2017)   (Jun 30 2022)



  News about Urogen Pharma Ltd Return on Investment ROI

UroGen Pharmas UGN-102 A Potential Breakthrough in Treating Non-Muscle Invasive Bladder Cancer

October 15, 2024

In a significant stride for both UroGen Pharma Ltd. and the realm of oncology, the company has announced the U.S. Food and Drug Administration’s (FDA) acceptance of its New Drug Application (NDA) for UGN-102, an investigational drug formulated as an intravesical solution containing mitomycin. This pivotal development presents an exciting opportunity for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC), a condition that has long been challenging to manage.UroGen Pharma Ltd. (Nasdaq: URGN), headquartered in Princeton, N.J. has built its reputation on creating innovative solutions specifically targeting urothelial and specialty cancers. The acceptance of UGN-102’s NDA marks a pivotal moment in the company’s quest to bring forth new treatment options for patients battling NMIBC, a form of cancer that, while often manageable, still presents significant burdens to patient quality of life.






Financial Statements
Urogen Pharma Ltd's III. Quarter Investments $ 198 Millions URGN's Balance sheet
Urogen Pharma Ltd's III. Quarter Income $ -1 Millions Quarterly URGN's Income Statement
URGN's Income by Division See URGN's Income by Division


URGN Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 154 237 144 112 97
Y / Y Investment Growth -34.93 % 64.15 % 29.12 % 14.72 % -1.72 %
Net Income in Millions -153 -127 -102 -110 -111
Y / Y Net Income Growth - - - - -
Annual Return On Investment -99.65 % -53.59 % -70.89 % -98.28 % -113.82 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
URGN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for URGN's Competitors
Subscribers only: Roi for Urogen Pharma Ltd's Suppliers
Subscribers only: Return On Investment for URGN's Customers

Other Ratios
URGN's Roa URGN's Inventory Turnover Ratio URGN's Growth Rates URGN's Dividend Statistics
URGN's Profitability Ratios URGN's Asset Turnover Ratio URGN's Dividend Growth
URGN's Roe URGN's Valuation Ratios URGN's Financial Strength Ratios URGN's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI


Date modified: 2026-11-07T13:22:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.